Ocrelizumab Biosimilar (BIOCAD)

N/A

Report date: 2026/02/26 20:00:22

Base Information

Drug NameOcrelizumab Biosimilar (BIOCAD)
Drug Alias NameBCD-281BCD281
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAnti-CD20Antibody-dependent cell-mediated cytotoxicity (ADCC) effectsCD20-directed cytolytic effects
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsMultiple Sclerosis, Relapsing-Remitting
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesBIOCAD JSC
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis, Relapsing-Remitting
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A